Full history for every metric is available with a Kvantra account
Abcam plc (ABCM)
Key financial summary
Financials in GBP| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 233 | 260 | 260 | 298 | 472 | 362 | 370 |
| Operating profit | £m | 54 | 73 | |||||
| Net profit | £m | 62 | 45 | 13 | 15 | 18 | -8 | 7 |
| EPS reported | £ | -0.04 | 0.03 | |||||
| Operating cashflow per share | £ | 0.13 | 0.13 | |||||
| Capex per share | £ | 0.18 | 0.18 | |||||
| FCF per share | £ | -0.06 | -0.06 | |||||
| Free cash flow | £m | -13 | 4 | |||||
| Net debt | £m | 135 | 39 | |||||
| Book value equity | £m | 727 | 719 | |||||
| Book value per share | £ | 3.18 | 3.09 | |||||
| Number of shares | m | 228.7 | 232.7 | |||||
| DPS (TTM paid) | £ | 0.11 | 0.00 |
Financial summary
Financials in GBP| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.05 | 5.80 | |||||
| P/S LTM | x | 8.13 | 11.27 | |||||
| P/FCF LTM | x | -233.48 | 992.74 | |||||
| EV/EBITDA LTM | x | 72.05 | 69.93 | |||||
| EV/Sales LTM | x | 8.51 | 11.38 | |||||
| Earnings Yield LTM | % | -0.29% | -0.21% | |||||
| FCF Yield | % | -0.43% | 0.10% | |||||
| Quality | ||||||||
| ROE | % | -1.17% | -1.23% | |||||
| ROIC | % | 2.98% | 2.98% | |||||
| Operating margin | % | 14.87% | 14.87% | |||||
| Gross margin | % | 74.79% | 74.79% | |||||
| FCF/Sales | % | -3.48% | -3.48% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | -1.58% | |||||
| Sales Growth YoY | % | -23.36% | +2.22% | |||||
| Net Income Growth YoY | % | - | +1.50% | |||||
| FCF Growth | % | - | -92.70% | |||||
| Operating Profit Growth | % | +14.97% | +129.28% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.85% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -294.12% | -294.12% | |||||
| FCF/Debt | x | -0.06 | 0.02 | |||||
| Net Debt/EBITDA | x | 3.16 | 3.16 | |||||
| EBIT/Net interest | x | 9.96 | 9.96 | |||||
| Net debt/market cap | % | 4.59% | 0.93% | |||||
| Net debt/Equity | x | 0.19 | 0.05 | |||||
| Gross debt/equity | x | 0.31 | 0.30 | |||||
Company overview
Abcam plc operates as a prominent life science enterprise, dedicated to the innovation, creation, and supply of crucial reagents and instruments. These fundamental resources are instrumental in supporting diverse scientific investigations, diagnostic applications, and the advancement of pharmaceutical drug discovery initiatives. Its comprehensive product portfolio features primary and secondary antibodies, conjugated antibodies paired with their respective kits, both singleplex and multiplex immunoassays, as well as a variety of proteins and peptides, including cytokines. Furthermore, the company provides edited cell lines, lysates, cellular activity kits, miRNA kits, biochemical compounds, and specialized tools for analyzing cell signaling pathways. Abcam serves a broad customer base, encompassing researchers and scientists within academic and institutional environments, alongside professionals at pharmaceutical, biotechnology, and diagnostic companies. The company boasts a global presence, conducting operations across the Americas, Europe, the Middle East, Africa, China, Japan, and the wider Asia Pacific region. Product distribution is primarily facilitated via its online platform. Founded in 1998, Abcam plc is headquartered in Cambridge, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Abcam plc (ABCM)
Abcam plc operates as a prominent life science enterprise, dedicated to the innovation, creation, and supply of crucial reagents and instruments. These fundamental resources are instrumental in supporting diverse scientific investigations, diagnostic applications, and the advancement of pharmaceutical drug discovery initiatives. Its comprehensive product portfolio features primary and secondary antibodies, conjugated antibodies paired with their respective kits, both singleplex and multiplex immunoassays, as well as a variety of proteins and peptides, including cytokines. Furthermore, the company provides edited cell lines, lysates, cellular activity kits, miRNA kits, biochemical compounds, and specialized tools for analyzing cell signaling pathways. Abcam serves a broad customer base, encompassing researchers and scientists within academic and institutional environments, alongside professionals at pharmaceutical, biotechnology, and diagnostic companies. The company boasts a global presence, conducting operations across the Americas, Europe, the Middle East, Africa, China, Japan, and the wider Asia Pacific region. Product distribution is primarily facilitated via its online platform. Founded in 1998, Abcam plc is headquartered in Cambridge, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free